Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease

Seminars in Hematology

Volumn 41, Issue SUPPL. 6, 2004, Pages 11-16

  Saunthararajah, Yogen ^a   Desimone, Joseph ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUTYRIC ACID; CYTOSINE; CYTOTOXIC AGENT; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; ENZYME INHIBITOR; GAMMA GLOBIN; HEMOGLOBIN F; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE CHEST SYNDROME; BETA THALASSEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DNA METHYLATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; GENE EXPRESSION; HUMAN; METABOLIC DISORDER; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROMOTER REGION; SICKLE CELL ANEMIA; SIDE EFFECT; STROKE; TESTIS CANCER; THALASSEMIA; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR CELL LINE;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; FETAL HEMOGLOBIN; HUMANS;

EID: 7644223139     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.08.003     Document Type: Conference Paper

References (47)

1. O.S. Platt, D.J. Brambilla, W.F. Rosse Mortality in sickle cell disease. Life expectancy and risk factors for early death N Engl J Med 330 1994 1639 1644
2. J. Watson The significance of the paucity of sickle cells in newborn Negro infants Am J Med Sci 215 1948 419 423
3. C.L. Conley, D.J. Weatherall, S.N. Richardson Hereditary persistence of fetal hemoglobin A study of 79 affected persons in 15 Negro families in Baltimore Blood 21 1963 261 281
4. R.P. Perrine, M.E. Pembrey, P. John Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects Ann Intern Med 88 1978 1 6
5. M.A. Goldberg, M.A. Husson, H.F. Bunn Participation of hemoglobins A and F in polymerization of sickle hemoglobin J Biol Chem 252 1977 3414 3421
6. R.L. Nagel, R.M. Bookchin, J. Johnson Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S Proc Natl Acad Sci U S A 76 1979 670 672
7. F. Mavilio, A. Giampaolo, A. Care Molecular mechanisms of human hemoglobin switching Selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts Proc Natl Acad Sci U S A 80 1983 6907 6911
8. J. DeSimone, P. Heller, L. Hall 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons Proc Natl Acad Sci U S A 79 1982 4428 4431
9. T.J. Ley, J. DeSimone, N.P. Anagnou 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia N Engl J Med 307 1982 1469 1475
10. T.J. Ley, J. DeSimone, C.T. Noguchi 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia Blood 62 1983 370 380
11. S. Charache, G. Dover, K. Smith Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex Proc Natl Acad Sci U S A 80 1983 4842 4846
12. G.J. Dover, R.K. Humphries, N. Young Pharmacologic manipulation of fetal hemoglobin synthesis Prog Clin Biol Res 191 1985 447 454
13. C.H. Lowrey, A.W. Nienhuis Brief report Treatment with azacitidine of patients with end-stage beta-thalassemia N Engl J Med 329 1993 845 848
14. B.I. Carr, J.G. Reilly, S.S. Smith The tumorigenicity of 5-azacytidine in the male Fischer rat Carcinogenesis 5 1984 1583 1590
15. B.I. Carr, S. Rahbar, Y. Asmeron Carcinogenicity and haemoglobin synthesis induction by cytidine analogues Br J Cancer 57 1988 395 402
16. S. Charache, M.L. Terrin, R.D. Moore Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia N Engl J Med 332 1995 1317 1322
17. M. Koshy, L. Dorn, L. Bressler 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia Blood 96 2000 2379 2384
18. J. DeSimone, M. Koshy, L. Dorn Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia Blood 99 2002 3905 3908
19. Y. Saunthararajah, C.A. Hillery, D. Lavelle Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease Blood 102 2003 3865 3870
20. R. Juttermann, E. Li, R. Jaenisch Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation Proc Natl Acad Sci U S A 91 1994 11797 11801
21. M. Milhem, N. Mahmud, D. Lavelle Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A Blood 103 2004 4102 4110
22. J.P. Issa, G. Garcia-Manero, F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
23. J.R. Landolph, P.A. Jones Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T 1/2 clone 8 and V79 cells Cancer Res 42 1982 817 823
24. D.B. McGregor, A.G. Brown, P. Cattanach TFT and 6TG resistance of mouse lymphoma cells to analogs of azacytidine Carcinogenesis 10 1989 2003 2008
25. L. Jackson-Grusby, P.W. Laird, S.N. Magge Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase Proc Natl Acad Sci U S A 94 1997 4681 4685
26. H. Marquardt Induction of malignant transformation and mutagenesis in cell cultures by cancer chemotherapeutic agents Cancer 40 1977 1930 1934
27. A. Eden, F. Gaudet, A. Waghmare Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
28. F. Gaudet, J.G. Hodgson, A. Eden Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
29. A.S. Yang, M.R. Estecio, G. Garcia-Manero Comment on Chromosomal instability and tumors promoted by DNA hypomethylation and Induction of tumors in mice by genomic hypomethylation Science 302 2003 1153
30. M. Lubbert, P. Wijermans, R. Kunzmann Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine Br J Haematol 114 2001 349 357
31. A.R. Karpf, A.W. Lasek, T.O. Ririe Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine Mol Pharmacol 65 2004 18 27
32. G. Leone, M.T. Voso, L. Teofili Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS Clin Immunol 109 2003 89 102
33. K.B. Glaser, M.J. Staver, J.F. Waring Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol Cancer Ther 2 2003 151 163
34. A.E. Chambers, S. Banerjee, T. Chaplin Histone acetylation-mediated regulation of genes in leukaemic cells Eur J Cancer 39 2003 1165 1175
35. C. Van Lint, S. Emiliani, E. Verdin The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation Gene Expr 5 1996 245 253
36. P.W. Laird, L. Jackson-Grusby, A. Fazeli Suppression of intestinal neoplasia by DNA hypomethylation Cell 81 1995 197 205
37. L.E. Lantry, Z. Zhang, K.A. Crist 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model Carcinogenesis 20 1999 343 346
38. F. McGregor, A. Muntoni, J. Fleming Molecular changes associated with oral dysplasia progression and acquisition of immortality Potential for its reversal by 5-azacytidine Cancer Res 62 2002 4757 4766
39. S.A. Belinsky, D.M. Klinge, C.A. Stidley Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer Cancer Res 63 2003 7089 7093
40. G.A. Thomas, E.D. Williams Production of thyroid tumours in mice by demethylating agents Carcinogenesis 13 1992 1039 1042
41. M.H. Steinberg, F. Barton, O. Castro Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia Risks and benefits up to 9 years of treatment JAMA 289 2003 1645 1651
42. M.H. Steinberg, Z.H. Lu, F.B. Barton Fetal hemoglobin in sickle cell anemia Determinants of response to hydroxyurea Multicenter Study of Hydroxyurea. Blood 89 1997 1078 1088
43. Y.M. Yang, B. Pace, D. Kitchens BFU-E colony growth in response to hydroxyurea Correlation between in vitro and in vivo fetal hemoglobin induction Am J Hematol 56 1997 252 258
44. G.F. Atweh, A.N. Schechter Pharmacologic induction of fetal hemoglobin Raising the therapeutic bar in sickle cell disease Curr Opin Hematol 8 2001 123 130
45. M.S. West, D. Wethers, J. Smith Laboratory profile of sickle cell disease: A cross-sectional analysis. The Cooperative Study of Sickle Cell Disease J Clin Epidemiol 45 1992 893 909
46. G.P. Rodgers, Y. Saunthararajah Advances in experimental treatment of beta-thalassaemia Expert Opin Investig Drugs 10 2001 925 934
47. W.H. Schultz, R.E. Ware Malignancy in patients with sickle cell disease Am J Hematol 74 2003 249 253